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Insulin-like growth factor (IGF)-I and insulin are essential for fetal growth. We investigated perinatal changes of both factors in 40
mothers and their 20 appropriate-for-gestational-age (AGA) and 20 intrauterine-growth-restricted (IUGR) fetuses and neonates
on day 1 (N1) and day 4 (N4) postpartum. Fetal and N1, but not N4, IGF-I levels were increased in AGA (P<. 001 and P = .037,
resp.). N1 insulin levels were lower in IUGR (P = .048). Maternal, fetal, and N1 IGF-I, and fetal insulin levels positively correlated
with customized centiles (r = .374, P = .035, r = .608, P<. 001, r = .485, P = .006, and r = .654, P = .021, resp.). Female
infants presented elevated fetal and N4 IGF-I levels (P = .023 and P = .016, resp.). Positive correlations of maternal, fetal, and
neonatal IGF-I levels, and fetal insulin levels with customized centiles underline implication of both hormones in fetal growth.
IUGR infants present gradually increasing IGF-I levels. Higher IGF-I levels are documented in females.
Copyright © 2007 Ariadne Malamitsi-Puchner et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Fetal and neonatal growth is a complex process involving ge-
netic, nutritional, hormonal, and environmental factors [1].
Itisoutofdoubtthatintrauterinegrowthrestriction(IUGR)
is associated with increased morbidity not only in the neona-
tal period, but also in childhood and later in adult life [1–3].
However,despiteextensiveresearch,theregulationofhuman
fetal growth still remains unclear [1].
Two peptide hormones, that share structural homology,
(insulin-like growth factor (IGF)-I and insulin), seem to be
the most important endocrine regulators of fetal growth [4].
IGF-I, which is produced by ﬁbroblasts and other cells of
mesenchymal origin, has many mitogenic actions including
stimulation of cellular growth, proliferation, and diﬀerenti-
ation [5]. It also shows anabolic eﬀects, enhancing glucose
and amino acid uptake [6] and appears to be the dominant
growth-promoting factor during the rapid phase of somatic
growth in late gestation [7]. In the fetus, IGF-I concentra-
tions are inﬂuenced by nutrients delivered through the pla-
centa rather than by fetal pituitary growth hormone (GH)
[8].
The role of insulin in fetal growth has also been clearly
identiﬁed [9]. Insulin may augment fetal growth by stimu-
lating the production of IGF-I [8]. Fetal insulin and IGF-I
act synergistically to enhance uptake and utilization of sub-
strates by the fetal tissues [8]. In IUGR pregnancies, changes
of the insulin substrate and IGF-I can be largely attributed
to poor nutrition with the majority of studies demonstrating
low serum IGF-I and insulin levels in late gestation and at
birth [10].
In postnatal life, nutrition, insulin, and IGF-I still
largelyregulategrowth[11].CirculatingIGF-Ilevelsincrease
rapidly after birth, primarily as a result of the onset of GH-
stimulated IGF-I production by the liver [8]. This transient
GH hypersecretion may drive the early growth acceleration
that occurs to some degree in virtually all SGA infants [10].
This study explored, for the ﬁrst time to our knowl-
edge, the concomitant changes of these two peptide hor-
mones in mother/infant pairs from IUGR and appropriate-
for-gestational-age(AGA)pregnancies,atcrucialtimepoints
of the perinatal period, characterizing intrauterine life, as
well as transition and stabilization to extrauterine one.
2. SUBJECTS AND METHODS
The Ethics Committee of our teaching hospital approved
the study protocol. Signed informed consent was acquired
from all participating mothers. Forty parturients giving con-
secutively birth either to 20 AGA or 20 asymmetric IUGR2 Mediators of Inﬂammation
full-termsingletoninfantswithabirthweightbeloworequal
to the 3rd customized centile were included in the study.
The gestation-related optimal weight (GROW) computer-
generated program [12, 13] was used to calculate the cus-
tomizedcentileforeachpregnancy,takingintoconsideration
signiﬁcant determinants of birth weight, as maternal height
and booking weight, ethnic group, parity, gestational age,
andgender[12].Gestationalagewasestimatedusingthedate
of the last menstrual period and early antenatal ultrasound.
Birth weight was measured with an electronic scale.
Nine of the 20 mothers with IUGR oﬀspring presented
preeclampsia [14]. The remaining 11 mothers presented
pregnancy-induced hypertension and suﬀered from vari-
ous pathological conditions, such as iron-deﬁcient anemia
(3 cases), gestational diabetes mellitus (2 cases), hypothy-
roidism (3 cases), extreme obesity (2 cases), and cardiac ar-
rhythmias (1 case). Five of the above women were smoking
more than 10 cigarettes per day during the whole duration of
pregnancy.
Doppler studies were performed in the IUGR group ev-
ery 10–15 days, starting from the 32nd gestational week.
Doppler studies of the uterine and umbilical arteries were se-
rially found to be in the upper physiological limits for gesta-
tional age in 13 cases, while in the remaining seven cases they
showed increased impedance to ﬂow(pulsatility index values
greater than the 95th percentile for the corresponding gesta-
tionalage).Regardingmiddlecerebralarteries,resistancewas
inthelowerphysiologicallimitsforgestationalageindicating
the initiation of blood ﬂow redistribution process. Neverthe-
less, amniotic ﬂuid was diminished in all IUGR cases. For
the evaluation of the amniotic ﬂuid, the largest ﬂuid column
on the vertical plane was assessed and was deﬁned as dimin-
ished, if <2cm. Furthermore, placental weight was reduced
ranging from 255 to 400g.
In contrast, in the AGA group, mothers were healthy and
were either nonsmokers or abstained from smoking during
pregnancy. Moreover, placentas were normal in appearance
and weight.
All neonates of both groups had no history of abnormal
perinatal clinical course, (e.g., perinatal asphyxia and infec-
tion) or identiﬁable congenital malformation and inherited
metabolic or genetic disorders. One- and ﬁve-minute Ap-
gar scores were ≥ 8 in all IUGR cases and AGA controls.
All neonates were breastfed and they all adapted well to ex-
trauterine life with no signs of respiratory distress, lethargy,
irritability, or poor feeding. The demographic data of partic-
ipating infants and their mothers are listed in Table 1.
Bloodwascollectedinpyrogen-freetubesfrom(i)moth-
ers during the ﬁrst stage of labor, or before receiving anes-
thesia in cases of elective cesarean section; (ii) the doubly
clamped umbilical cords, reﬂecting fetal state (mixed arte-
riovenous blood); and (iii) neonates on postpartum day 1
(N1) and day 4 (N4), characterizing transition and stabiliza-
tion to extrauterine life, respectively. Blood was allowed to
clot and was immediately separated by centrifugation. The
supernatant serum was kept frozen at −80◦C until assay.
IGF-I was measured by ELISA (Assay Designs Inc., 800
Technology Drive Ann Arbor, Mich, USA). The minimum
Table 1: Demographic data of participating appropriate for ges-
tational age (AGA) and intrauterine-growth-restricted (IUGR)
mother/infant pairs.
AGA (n = 20) IUGR (n = 20)
Mean Std. dev. Mean Std. dev.
Maternal age (years) 28 4 30.6 5.3
Parity
First 14 (70%) 11 (55%)
Second 6 (30%) 7 (35%)
Other — 2 (10%)
Gestational age (weeks) 38.20 0.90 38.10 0.70
Mode of delivery
Vaginal 12 (60%) 8 (40%)
Cesarean section 8 (40%) 12 (60%)
Birth weight (g) 3467 274.9 2342.5 228.57
Customized centile 75.6 7.56 1.5 1.5
Gender
Male 9 (45%) 11 (55%)
Female 11 (55%) 9 (45%)
detectable concentration, intra- and interassay coeﬃcients of
variation (CV)% were 187pg/mL, 4.9% and 7.1%, respec-
tively.
The determination of insulin levels was performed by
M i c r o p a r t i c l eE n z y m eI m m u n o a s s a y( A b b o tD i a g n o s t i c s
(Axsym System), Wiesbaden, Germany). The minimum de-
tectable concentration, intra- and interassay CV% were
<1μU/ml, 4.1% and 5.3%, respectively.
3. STATISTICAL ANALYSIS
IGF-I data presented normal distribution (Kolmogorov-
Smirnov test). The repeated measures analysis of variance
with Bonferroni correction for multiple comparisons was
used to assess statistically signiﬁcant diﬀerences between the
four measurements (maternal, fetal, N1, N4) of IGF-I levels.
Insulin levels were not normally distributed (Kolmogorov-
Smirnov test); therefore, nonparametric procedures (Mann-
Whitney U test and Wilcoxon sum-rank test) were used.
Pearson or Spearman’s correlation coeﬃcient, where appro-
priate, was used to detect positive or negative correlations.
Values of P<. 05 were considered statistically signiﬁcant.
4. RESULTS
In the AGA group, maternal IGF-I levels were elevated com-
pared to fetal (P<. 001) and neonatal day-1 (P<. 001) and
day-4 (P<. 001) levels after adjustment for multiple com-
parisons (Figure 1). Similarly, fetal IGF-I levels were signiﬁ-
cantly elevated compared to neonatal day-1 (P<. 001) and
day-4 (P<. 001) (Figure 1).
In the IUGR group, maternal IGF-I levels were signiﬁ-
cantly elevated compared to fetal (P<. 001), neonatal day-1
(P<. 001) and day-4 (P<. 001) levels after adjustment for
multiple comparisons (Figure 1). Fetal IGF-I levels were sig-
niﬁcantly elevated compared to neonatal day-1 (P<. 001)Ariadne Malamitsi-Puchner et al. 3
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Figure 1: Box and whiskers plots of the concentration of IGF-
I in maternal (MS), fetal (UC), neonatal day-1 (N1), and day-4
(N4) serum samples from appropriate-for-gestational-age (AGA)
and intrauterine-growth-restricted (IUGR) groups. Each box rep-
resents the median concentration with the interquartile range (25th
and 75th percentiles). The upper and lower whiskers represent the
range.
and day-4 (P = .002) IGF-I levels (Figure 1). Additionally,
maternal insulin levels were signiﬁcantly elevated compared
to fetal (P<. 001), neonatal day-1 (P = .001) and neonatal
day-4 (P = .022) levels.
Concerning diﬀerences between the groups, fetal and
neonatal day-1 IGF-I levels were signiﬁcantly increased in
the AGA group (by 32.6ng/mL and 4.2ng/mL on average,
resp.) compared to the IUGR one, after controlling for gen-
der and adjusting for multiple comparisons (regression co-
eﬃcient b: 32.6, SE: 7.4, P<. 001, 95% conﬁdence inter-
val (CI): 17.5–47.7, and regression coeﬃcient b: 4.2, SE: 1.9,
P = .037, 95% CI: 0.3–8.2, resp.). No signiﬁcant diﬀer-
ences were found in neonatal day-4 IGF-I levels between the
two groups. Neonatal day-1 insulin levels were signiﬁcantly
lower in IUGR neonates compared to AGA ones (P = .048)
(Figure 2).
Maternal,fetal,andneonatalday-1IGF-Ilevelspositively
correlated with customized centiles (r = .374, P = .035, r =
.608, P<. 001, and r = .485, P = .006, resp.). Moreover, fetal
insulin levels positively correlated with customized centiles
(r = .654, P = .021). In the AGA group, maternal insulin
levels positively correlated with maternal IGF-I levels (r =
.606, P = .037).
Females presented elevated fetal and neonatal day-4 IGF-
Il e v e l s( b y1 7 . 0 n g / m La n d7 . 5 n g / m Lo na v e r a g e ,r e s p . )
compared to males (regression coeﬃcient b: 17.0, SE: 7.1,
P = .023, 95% CI: 2.5–31.5, and regression coeﬃcient b:
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Figure 2: Box and whiskers plots of the concentration of insulin
in maternal (MS), fetal (UC), neonatal day-1 (N1), and day-4
(N4) serum samples from appropriate-for-gestational-age (AGA)
and intrauterine-growth-restricted (IUGR) groups. Each box rep-
resents the median concentration with the interquartile range (25th
and 75th percentiles). The upper and lower whiskers represent the
range.
7.5, SE: 2.9, P = .016, 95% CI: 1.5–13.5, resp.). Females also
presented elevated day-1 IGF-I levels (by 3.8ng/mL on av-
erage) compared to males (regression coeﬃcient b:3 . 8 ,S E :
1.9, P = .051, 95% CI: 0.02–7.5); however this diﬀerence was
indicatively signiﬁcant (Figure 3).
5. DISCUSSION
ThisstudyinvestigatedconcomitantchangesofIGF-Iandin-
sulin at crucial perinatal time points in mother/infants pairs
from IUGR and AGA pregnancies. It is known that IGF-I is
a major hormonal determinant of fetal growth [15]; thus,
IGF-I cord levels correlate with birth weight [16–19], a ﬁnd-
ing also recorded in both AGA and IUGR groups of our
study granted that customized centiles represent adjusted
birth weight [12, 13]. Moreover, reduced fetal IGF-I levels
have been found to be predictive of intrauterine growth re-
striction [18, 20]. In this respect, we also demonstrated sig-
niﬁcantly lower fetal and neonatal day-1 IGF-I levels in the
IUGR group.
A previous report stated that SGA newborns have lower
IGF-I levels than AGA ones during the ﬁrst week of life
[11]. It has been suggested that reduced IGF-I levels in
SGA infants may determine the rate of subsequent catchup
growth [11]. In our study, signiﬁcantly lower IGF-I levels
weredocumentedinIUGRday-1neonates;however,thisdif-
ference became statistically non signiﬁcant on the 4th day4 Mediators of Inﬂammation
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Figure 3: Box and whiskers plots of the concentration of IGF-I in
fetal (UC), neonatal day-1 (N1), and day-4 (N4) serum samples
from males and females. Each box represents the median concen-
trationwiththeinterquartilerange(25thand75thpercentiles).The
upper and lower whiskers represent the range.
postpartum, indicating a rise of serum IGF-I levels. Taken
that IGF-I levels are an indicator of nutritional status [21]
a n dl o wb i r t hw e i g h ti sk n o w nt ol e a dt oc a t c h u pg r o w t hi n
the neonate [22], we might speculate that catchup growth
starts early after birth, provided that IUGR neonates are ade-
quately fed, as was the case in our study (infants were breast-
fed ad libidum).
Up till now, many studies have failed to show a direct
relationship between maternal serum IGF-I levels at term
and birth weight in normal pregnancies [23, 24]. Holmes
et al. reported an association between maternal IGF-I and
birth weight in women with placental dysfunction, but not
in healthy pregnant women [25]. Our data show a strong as-
sociation between maternal circulating IGF-I levels and cus-
tomizedcentilesinbothnormalandIUGRpregnancies.This
is comparable with the ﬁnding of Boyne et al. who reported
that maternal IGF-I levels increase with advancing gestation
and correlate well with birth weight [4].
On the other hand, there is no prior evidence of
transplacental transfer of maternal IGF-I, causing a direct
growth-promoting/mitogenic eﬀect on the fetus [4, 26].
The lack of correlation between maternal and fetal IGF-I,
as well as the signiﬁcantly higher IGF-I levels in maternal
serum compared with cord blood in our study further
support this concept. Hence, if maternal IGF-I does have
an impact on fetal growth, the mechanism is probably
mediated by increased nutrient supply, especially glucose,
facilitating fetoplacental anabolism [4], as earlier suggested,
based on the positive association between changes of IGF-I
throughout gestation and placental size [24].
This study also shows a signiﬁcant decrease of IGF-I on
the ﬁrst day postpartum in both IUGR and AGA groups.
This ﬁnding could be attributed to the elimination of decid-
uas and placenta with birth, which represent two important
sources of IGF-I during pregnancy [27].
It has been previously shown that IGF-I increases ma-
ternal insulin sensitivity, suppresses insulin production, and
increases the transplacental transfer of glucose in an animal
model [28]. In our study, a positive correlation between ma-
ternal IGF-I and insulin levels was demonstrated in the AGA
group. The eﬀects of circulating IGF-I on increasing insulin
sensitivityarewellrecognized[29].However,ithasbeenpos-
tulatedthatIGF-Imayhaveafurtherimportantroleinmain-
taining β-cell mass and insulin secretory response to glucose
[30].
On the other hand, in our IUGR group, maternal in-
sulin levels were signiﬁcantly elevated compared to fetal and
neonatal days 1 and 4. This ﬁnding may be attributed to
maternal pathologic conditions, associated with IUGR [31],
as well as to the altered endocrine environment observed
in these women during pregnancy [32]. These hormonal
changesincludeincreasedmaternalinsulinlevels,asreported
inalow-proteinanimalmodelofintrauterinegrowthrestric-
tion [32].
Moreover, insulin has a central role in regulating fe-
tal growth [9]. Body weight at birth is associated with the
amountoffunctioningpancreatictissue,withhyperinsuline-
mic babies being macrosomic and SGA babies having re-
duced β-cell mass [9]. A positive correlation between birth
weight and cord insulin levels [16, 19] has been found, al-
though some controversy exists [11, 33]. We report a strong
correlation between fetal insulin levels and customized cen-
tiles.
In addition, insulin levels were lower on the ﬁrst day of
life in IUGR neonates compared to controls. This observa-
tion is in accordance with recent studies indicating that SGA
newborns have signiﬁcantly lower insulin levels and per-
haps initially increased insulin sensitivity than AGA controls
[34, 35]; this fact could possibly contribute to rapid early
weight gain [36].
Finally, we observed, in both groups, a gender diﬀerence
in the fetal and neonatal IGF-I concentrations, which were
higherwhentheneonatewasfemale,ashasbeendescribedin
older children [37, 38]. Results from measurements of IGF-
I in serum of fetuses and preterm or term newborn infants
have been more variable, as some groups ﬁnd no diﬀerence
in serum IGF-I concentrations between the male and female
genders[39,40];othersreporthigherIGF-Iingirlsthanboys
[41, 42]. However, this gender diﬀerence has not been, up till
now, described in IUGR neonates. The reason for this gen-
der diﬀerence is not clear, but it has been suggested that sex
steroids could inﬂuence the secretion of IGF-I in utero [43].
Overall,ourdataindicatethatagendereﬀectonIGF-I,which
isproducedbythefetoplacentalunit,isoperativeinearlylife:
thedeterminantsandsigniﬁcanceofthisdiﬀerenceremainto
be studied.Ariadne Malamitsi-Puchner et al. 5
In conclusion, the positive correlations of maternal, fetal,
and neonatal IGF-I levels, as well as fetal insulin levels with
customized centiles underline the crucial role of both hor-
mones in fetal growth. IUGR infants present lower, but grad-
ually increasing, IGF-I levels, possibly predicting initiation
of catchup growth. Insulin levels are lower in IUGR neonates
on day 1 postpartum. Higher IGF-I levels in females may be
attributed to inﬂuence of sex steroids in utero.
However, the exact mechanisms underlying the implica-
tions of IGF-I and insulin in the perinatal period of IUGR
still need to be elucidated.
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